UK markets closed
NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.14 -2.79 (-3.41%) GOLD FUTURES
2,309.90 +7.00 (+0.30%) DOW
37,954.46 +138.54 (+0.37%) Bitcoin GBP
45,778.91 -2,294.55 (-4.77%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:43PM EDT. Market open.
| Previous close | 137.54 |
| Open | 140.18 |
| Bid | 138.16 x 100 |
| Ask | 138.51 x 100 |
| Day's range | 136.01 - 142.36 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 888,567 |
| Market cap | 13.907B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 55.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | N/A |
- Investor's Business Daily
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Neurocrine stock rose Wednesday after the leading biotech topped Wall Street's sales expectations and wrapped a key regulatory filing.
- Zacks
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.